Factors associated with late risks of breast cancer-specific mortality in the SEER registry
Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research And Treatment 2021, 189: 203-212. PMID: 33893907, PMCID: PMC8302525, DOI: 10.1007/s10549-021-06233-4.Peer-Reviewed Original ResearchConceptsBC-specific mortalityHR-positive breast cancerHR-negative breast cancerBreast cancerHR statusCumulative riskBreast cancer-specific mortalityCancer-specific mortalityT1a/bHormone receptor statusYear of diagnosisKaplan-Meier analysisLong-term riskBC deathConclusionThe risksGray regressionN2 diseaseLate relapseReceptor statusLate recurrenceSEER registryLater riskClinical trialsYear 5PatientsTwenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade